If you're following GLP-1 research, retatrutide is the name to know. It's a triple agonist hitting GIP, GLP-1, and glucagon receptors simultaneously.
Why it matters:
Current status:
The interesting question: Does triple agonism actually translate to meaningfully better outcomes than dual (tirzepatide) or single (semaglutide) agonism? Or are we hitting a ceiling of diminishing returns?
What's everyone's read on this? Is triple agonism the future or are we overcomplicating things?
@wooddhaven wrote:
Interesting that it says not yet available through research vendors.
I think the consensus is that Reta is a game changer with its ability to improve health multiple ways.
I just switched to Reta from Tirz and am really interested to see how it works out for me.
...
thanks, I'll edit that... incorrect information.. thanks for pointing it out, what's even more interesting their working on GLP-4's already.
@shueeet wrote:
Anyone have a good vendor for Reta ?
There is plenty of good vendors who do testing that have this product.
